Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Gleevec/Glivec

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gleevec/Glivec was produced by Novartis.

FDA clears Blueprint’s $32k-per-month GI cancer drug

FDA clears Blueprint’s $32k-per-month GI cancer drug

Chemotherapy and radiotherapy is notoriously ineffective in GIST. At the moment the standard approach to treating patients who aren’t eligible for surgery is older kinase inhibitor drugs like Novartis’ Glivec

Novartis aims for 10 blockbuster launches by 2020

Novartis aims for 10 blockbuster launches by 2020 On the downside, revenues from post-patent expiry cancer drug Glivec continued to decline (down 20% to $1.56bn).

Biopharma's Future: Made in China

Biopharma's Future: Made in China Novartis’ leukaemia treatment Glivec.

Novartis gets speedy reviews for new Kymriah filings

Novartis gets speedy reviews for new Kymriah filings as Glivec (imatinib) are succumbing to generic competition.

Novartis Oncology head Bruno Strigini to retire

Novartis Oncology head Bruno Strigini to retire He has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics